Tumor Inflammation Signature (TIS) (RUO)
Helping Your Research
NanoString’s Tumor Inflammation Signature (TIS) (RUO) measures a peripherally suppressed adaptive immune response and helps distinguish immune “hot” from “cold” tumors. The Tumor Inflammation Signature includes 18 functional genes known to be associated with response to PD-1/PD-L1 inhibitors. The Tumor Inflammation Signature includes 4 areas of immune biology: IFN-ү-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance genes.
When used with the nCounter® platform, the Tumor Inflammation Signature has proven performance with RNA extracted from FFPE samples. The Tumor Inflammation Signature can be purchased in many different product formats including Custom CodeSet and it is included in select prebuilt panels (PanCancer IO 360™ Panel, Breast Cancer 360™ Panel, Tumor Signaling 360™ Panel, Immune Exhaustion Panel, and the Autoimmune Profiling Panel). The Tumor Inflammation Signature can also be added as a Plus Product spike-in to any panel or Custom CodeSet.
The Tumor Inflammation Signature Assay At Work
The TIS Signature
The Tumor Inflammation Signature was developed and trained in collaboration with Merck using data from different pembrolizumab clinical studies. Signature development started with a small pilot of 19 melanoma patients and the gene expression profiles (GEP) were ultimately defined using data from 220 patients with 9 cancers. The predictive value was independently confirmed and compared with that of PD-L1 immunohistochemistry in 96 patients with head and neck squamous cell carcinoma. The Tumor Inflammation Signature correlates response to single agent Pembrolizumab independent of tumor cell of origin.1Ayers, Mark, et al. “IFN-y-related mRNA profile predicts clinical response to PD-1 blockade.” The Journal of Clinical Investigation 127.8 (2017).
Please visit our TIS GEP: Use Cases in Sample Stratification, Assessment of Treatment Effect, and as a Component of a Multivariate Biomarker blog for more detailed information on TIS.
Product Specifications
Catalog Information
The TIS Data Analysis Report
There are several options for obtaining Tumor Inflammation Signature scores. Data generated using the PanCancer IO 360™ Panel or the Breast Cancer 360™ Panel can be used to generate a 360 Data Analysis Report. Individual TIS signature reports can be generated for other panel data containing the signature. You can access Tumor Inflammation Signature analysis using NanoString’s Data Analysis Services or several Contract Research Organizations.
Single Sample Analysis
Publications & Posters
Assessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse Model
Previous work done by our laboratory described the use of an immunocompetent spontaneous melanoma-prone mouse model, TGS (TG-3/SKH-1), to evaluate treatment outcomes using inhibitors of glutamatergic signaling and immune checkpoint for 18 weeks. We showed a significant therapeutic efficacy with a notable sex-biased response in male mice.
Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones
High-grade serous ovarian carcinoma (HGSOC) is genetically unstable and characterised by the presence of subclones with distinct genotypes. Intratumoural heterogeneity is linked to recurrence, chemotherapy resistance, and poor prognosis.
Spatially Segregated Macrophage Populations Predict Distinct Outcomes In Colon Cancer
Tumor-associated macrophages are transcriptionally heterogeneous, but the spatial distribution and cell interactions that shape macrophage tissue roles remain poorly characterized. Here, we spatially resolve five distinct human macrophage populations in normal and malignant human breast and colon tissue and reveal their cellular associations.
Request a Quote
Contact our helpful experts and we’ll be in touch soon.
